Arbutus Biopharma
ABUS
ABUS
130 hedge funds and large institutions have $298M invested in Arbutus Biopharma in 2024 Q2 according to their latest regulatory filings, with 23 funds opening new positions, 49 increasing their positions, 30 reducing their positions, and 10 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more capital invested
Capital invested by funds: $ → $
25% more funds holding in top 10
Funds holding in top 10: 4 → 5 (+1)
10% more funds holding
Funds holding: 118 → 130 (+12)
4.78% more ownership
Funds ownership: 46.45% → 51.23% (+4.8%)
Holders
130
Holding in Top 10
5
Calls
$11M
Puts
$1.28M
Top Buyers
| 1 | +$37.5M | |
| 2 | +$5.19M | |
| 3 | +$3.75M | |
| 4 |
BlackRock
New York
|
+$3.55M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.2M |
Top Sellers
| 1 | -$9.72M | |
| 2 | -$5.72M | |
| 3 | -$5.67M | |
| 4 |
CC
Centiva Capital
New York
|
-$4.02M |
| 5 |
American Century Companies
Kansas City,
Missouri
|
-$333K |